Abstract
A 57-year-male was admitted with difficulty in swallowing, breathing, and speaking for 2 months, which increased in the evenings. The onset was insidious and gradually progressive. Clinical examination revealed diplopia on horizontal gaze and wasting of muscles: intercostal, sternocleidomastoid, and flexors of the neck. There was no history of chest or cardiac disease and his oxygen saturation was low and respiratory rate was high. The patient was intubated and a nasogastric tube was inserted. He was started on high-dose methylprednisolone and tab pyridostigmine with other supportive measures. Serum acetylcholine receptor antibody was positive. MRI of the brain and CT of the chest were normal. After 7 days, tracheotomy and percutaneous endoscopic gastrostomy insertion were done. The patient gradually improved and was shifted to the ward. He was discharged in stable condition after 3 weeks of hospital admission with closed tracheostomy and in situ percutaneous endoscopic gastrostomy. He was on a tapering dose of steroid and pyridostigmine (60 mg 5 times daily) at first follow-up. Six months after admission his percutaneous endoscopic gastrostomy tube was removed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hughes T. The early history of myasthenia gravis. Neuromuscul Disord. 2005;15:878–86.
Li Y, Arora Y, Levin K. Myasthenia gravis: newer therapies offer sustained improvement. Cleve Clin J Med. 2013;80(11):711–2.
Alkhawajah NM, Oger J. Late onset myasthenia gravis: a review when incidences in older adults keeps increasing. Muscle Nerve. 2013;48(5):705–10.
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Disord. 2007;2:44.
Namba T, Brunner NG, Grob D. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine. 1978;57:411–33.
Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175:408–18.
Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40.
Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16–23.
Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol. 2000;111:1203–7.
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–8.
Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Auto antibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69:418–22.
Ropper AH, Samuels MA. Adams and Victor’s principles of neurology. 9th ed. New York: McGraw Hill; 2009. p. 1241–2.
Sarrigiannis PG, Kennett RP, Read S, Farrugia ME. Single fiber EMG with a concentric needle electrode validation in myasthenia gravis. Muscle Nerve. 2006;33:61–5.
Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet. 1934;223:1200–1.
Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol. 2004;24:41–8.
Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291–8.
Simmons WD, Rayhill SC, Sollinger H. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17:75–92.
Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56:185–96.
Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 1977;297:1134–40.
Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gamma globulin for myasthenia gravis. Lancet. 1984;1:406–7.
Ipe TS, Davis AR, Raval JS. Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. Front Neurol. 2021;12:662856.
Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, MG Study Group, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48:76–84.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419–25.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pokharel, B.R. (2024). Myasthenia Gravis. In: Oli, K.K., Shrestha, G.S., Ojha, R., Pal, P.K., Pandey, S., Das, B. (eds) Case-based Approach to Common Neurological Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-99-8676-7_17
Download citation
DOI: https://doi.org/10.1007/978-981-99-8676-7_17
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-8675-0
Online ISBN: 978-981-99-8676-7
eBook Packages: MedicineMedicine (R0)